Baird raised the firm’s price target on Agenus (AGEN) to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where the cmpoany is evaluating multiple proposals which are expected to bring in capital.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Agenus’s Regulatory and Clinical Developments Prompt Neutral Stance Amid Uncertain FDA Pathway
- Agenus Inc. Reports Q1 2025 Progress and Financials
- Agenus Inc. Earnings Call: Optimism Amid Challenges
- Agenus files to sell 165,000 shares of common stock for holders
- Agenus Hold Rating: Uncertainty Amid Funding and Regulatory Challenges